Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicenter, placebo-controlled, double-blind study aiming to build upon and strengthen the existing evidence base supporting the efficacy and safety of a single ABO treatment for the treatment of moderate to severe glabellar lines

Next Previous
Trial Profile

A prospective, multicenter, placebo-controlled, double-blind study aiming to build upon and strengthen the existing evidence base supporting the efficacy and safety of a single ABO treatment for the treatment of moderate to severe glabellar lines

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 Apr 2020 New trial record
  • 01 Jan 2020 Primary endpoint (proportion of treatment responders at Day 30 was greater in the ABO treatment group compared with placebo, assessed by both investigators and subjects at maximum frown) has been met published in the Dermatologic Surgery

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top